The Europe Emphysema Treatment Market would witness market growth of 6.6% CAGR during the forecast period (2022-2028).
Emphysema is a major subclass of chronic obstructive pulmonary disease (COPD) if it is associated with significant airflow limitation. COPD is a progressive lung disease characterized by long-term breathing complications and poor airflow. Even in the absence of COPD, emphysema on a CT lung scan is associated with a significantly increased risk of death among cigarette users. The first signs of emphysema might manifest differently in each individual with the disease. A cough (with or without sputum), wheezing, a rapid breathing rate, shortness of breath on exercise, and a sense of tightness in the chest may be present. There is a possibility of frequent infections with the cold or flu.
Damage to the air sacs, which may be caused by emphysema, can result in a change in the form of the air sacs or, more often, their destruction. This causes a decrease in the amount of gas that is exchanged in the lungs, which leads to trouble breathing. In addition, the damage done to the thin membrane that lines the air sacs cannot be repaired, resulting in a decreased amount of oxygen traveling through the bloodstream.
In England, smoking is expected to be the top avoidable cause of sickness and premature death in 2019, taking the lives of around 74,600 individuals. It is anticipated that there were 506,100 smoking-related hospital admissions in England in the year 2019 to 2020; this is equivalent to about 1,400 entries on a daily basis. Smokers make up one in every four people occupying a bed in a hospital. In addition, smokers go to the doctor 35% more often than non-smokers.
It is anticipated that the number of people living with chronic obstructive pulmonary disease (COPD) in France would rise to 2.8 million by 2025, from the current prevalence estimate of 2.6 million. In addition, there is a dearth of evidence on treating COPD within the context of private healthcare settings. These factors provide potential expansion prospects for investors operating in the regional emphysema market.
The Germany market dominated the Europe Emphysema Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $361.6 million by 2028. The UK market is anticipated to grow at a CAGR of 5.7% during (2022 - 2028). Additionally, The France market would experience a CAGR of 7.4% during (2022 - 2028).
Based on Medication Type, the market is segmented into Bronchodilators, Steroids, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Emphysema Treatment Market will Hit $6.05 Billion by 2028, at a CAGR of 6.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Orion Corporation, GlaxoSmithKline PLC, Pfizer, Inc., Hikma Pharmaceuticals PLC, Boehringer Ingelheim International GmbH and Verona Pharma Plc.
By Medication Type
By Distribution Channel
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 